Biphasic Insulin Aspart Given Thrice Daily is as Efficacious as a Basal-Bolus Insulin Regimen with Four Daily Injections

2006 ◽  
Vol 114 (09) ◽  
pp. 511-519 ◽  
Author(s):  
R. Ligthelm ◽  
U. Mouritzen ◽  
H. Lynggaard ◽  
M. Landin-Olsson ◽  
C. Fox ◽  
...  
Keyword(s):  
Insulin Aspart ◽  
Insulin Regimen ◽  
Biphasic Insulin Aspart ◽  
Biphasic Insulin ◽  
Bolus Insulin ◽  
Basal Bolus

Safety and effectiveness of biphasic insulin aspart 30 in people with type 2 diabetes switching from basal-bolus insulin regimens in the A1chieve study

2014 ◽  
Vol 8 (2) ◽  
pp. 111-117 ◽  
Author(s):  
Guillermo Dieuzeide ◽  
Lee-Ming Chuang ◽  
Abdulrahman Almaghamsi ◽  
Alexey Zilov ◽  
Jian-Wen Chen ◽  
...  
Keyword(s):  
Type 2 Diabetes ◽  
Insulin Aspart ◽  
Biphasic Insulin Aspart ◽  
Biphasic Insulin ◽  
Biphasic Insulin Aspart 30 ◽  
Bolus Insulin ◽  
Basal Bolus

scholarly journals Faster Aspart: a fast-acting insulin analog for an optimal glycemic control

2021 ◽  
Vol 24 (3) ◽  
pp. 196
Author(s):  
Irace, C.
Keyword(s):  
Insulin Aspart ◽  
Therapeutic Option ◽  
Glycosylated Hemoglobin ◽  
Insulin Regimen ◽  
Chronic Complications ◽  
Acting Insulin ◽  
Clinical Benefits ◽  
Bolus Insulin ◽  
Basal Bolus ◽  
Fast Acting

The basal-bolus insulin regimen in the management of diabetes is essential to achieve the recommended glycosylated hemoglobin (HbA1c) to reduce the incidence or the progression of chronic complications. HbA1c is influenced by either fasting plasma glucose and post-prandial hyperglycemia. Faster Aspart is an insulin Aspart with two additional excipients, L-arginine and niacinamide, which provide a faster subcutaneous absorption, the earlier onset of appearance, and consequently the optimization of post-prandial glucose control. Faster Aspart has been widely investigated in the ‘‘onset’’ clinical trials, which show better post-prandial glycemic excursions and noninferiority compared to insulin Aspart with HbA1c reduction. Clinical evidence demonstrates that faster Aspart is a therapeutic option able to provide clinical benefits over the current rapid-acting insulin analogs in terms of improved meal-related glycaemic control in subjects with diabetes. KEY WORDS post-prandial hyperglycemia; cardiovascular disease; insulin treatment; faster-acting insulin; faster aspart.

scholarly journals Safety and Effectiveness of Switching from a Basal-only to Biphasic Insulin Aspart 30 Insulin Regimen

2013 ◽  
Vol 4 (2) ◽  
pp. 309-319 ◽  
Author(s):  
Jihad Haddad ◽  
Mohsen Khoshniatnikoo ◽  
Youcef Benabbas ◽  
Serdar Guler ◽  
Vinay Prusty ◽  
...  
Keyword(s):  
Insulin Aspart ◽  
Insulin Regimen ◽  
Biphasic Insulin Aspart ◽  
Biphasic Insulin ◽  
Biphasic Insulin Aspart 30

Postprandial versus preprandial dosing of biphasic insulin aspart in elderly type 2 diabetes patients

2004 ◽  
Vol 66 (1) ◽  
pp. 23-29 ◽  
Author(s):  
Mark L. Warren ◽  
Martin J. Conway ◽  
Leslie J. Klaff ◽  
Julio Rosenstock ◽  
Elsie Allen
Keyword(s):  
Type 2 Diabetes ◽  
Insulin Aspart ◽  
Biphasic Insulin Aspart ◽  
Biphasic Insulin ◽  
Diabetes Patients
Sign in / Sign up

Export Citation Format

Share Document